Get the Stockscreener App
21.28
3.30%
0.68
After Hours:
21.38
0.10
+0.47%
Beam Therapeutics Inc stock is traded at $21.28, with a volume of 2.19M.
It is up +3.30% in the last 24 hours and up +19.42% over the past month.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
See More
Previous Close:
$20.60
Open:
$20.88
24h Volume:
2.19M
Relative Volume:
0.89
Market Cap:
$2.15B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-11.76
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
+6.72%
1M Performance:
+19.42%
6M Performance:
-12.17%
1Y Performance:
-19.09%
1-Day Range:
$20.78
$21.50
1-Week Range:
$19.36
$21.59
52-Week Range:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
21.28 | 2.08B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.21 | 101.15B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.14 | 61.07B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.59 | 59.35B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.83 | 46.29B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.27 | 35.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-10-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Beam Therapeutics stock maintains Buy rating at H.C. Wainwright on pipeline progress - Investing.com
Beam Therapeutics (BEAM) Announces Acquisition of an Early-Stage Life Sciences Company - MSN
Woodline Partners LP Boosts Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
43,199 Shares in Beam Therapeutics Inc. $BEAM Acquired by Jacobs Levy Equity Management Inc. - MarketBeat
Wall Street Zen Downgrades Beam Therapeutics (NASDAQ:BEAM) to Sell - MarketBeat
Beam Therapeutics (BEAM): Assessing Valuation After Strategic Shift and Analyst Optimism on BEAM-302 Program - Yahoo Finance
Beam Therapeutics (NASDAQ:BEAM) Upgraded to "Hold" at Wall Street Zen - MarketBeat
BMO Capital Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $40 - 富途牛牛
Beam Therapeutics (NASDAQ:BEAM) Trading 21.3% HigherWhat's Next? - MarketBeat
Transcript : Beam Therapeutics Inc. Presents at H.C. Wainwright 27th Annual Global Investment Conference, Sep-08-2025 10 - MarketScreener
EcoR1 Capital LLC Makes New Investment in Beam Therapeutics Inc. $BEAM - MarketBeat
92,754 Shares in Beam Therapeutics Inc. $BEAM Bought by Allostery Investments LP - MarketBeat
Northern Trust Corp Has $16.67 Million Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
Is Beam Therapeutics Inc. trading at a discountShort Setup & Free Weekly Chart Analysis and Trade Guides - 강소기업뉴스
Tools to assess Beam Therapeutics Inc.’s risk profile2025 Market Outlook & Real-Time Market Trend Scan - Newser
What does recent volatility data suggest for Beam Therapeutics Inc.2025 Geopolitical Influence & Capital Protection Trading Alerts - Newser
Risk adjusted return profile for Beam Therapeutics Inc. analyzedPortfolio Performance Report & AI Enhanced Trade Execution Alerts - Newser
Tick level data insight on Beam Therapeutics Inc. volatility2025 Trade Ideas & Reliable Intraday Trade Plans - Newser
Is Beam Therapeutics Inc. likely to announce a buybackM&A Rumor & Smart Allocation Stock Reports - خودرو بانک
American Century Companies Inc. Has $1.94 Million Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Will Beam Therapeutics Inc. benefit from seasonality2025 Fundamental Recap & AI Forecasted Entry and Exit Points - خودرو بانک
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences - FinancialContent
Can technical indicators confirm Beam Therapeutics Inc.’s reversalJuly 2025 Recap & AI Powered Market Trend Analysis - Newser
Beam Therapeutics Inc. stock trendline breakdownSwing Trade & Verified Chart Pattern Trade Signals - Newser
Can Beam Therapeutics Inc. recover in the next quarterEarnings Risk Summary & Weekly Watchlist for Consistent Profits - Newser
Detecting price anomalies in Beam Therapeutics Inc. with AIPortfolio Profit Report & Breakout Confirmation Alerts - Newser
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Is this a good reentry point in Beam Therapeutics Inc.July 2025 Trends & Real-Time Chart Breakout Alerts - Newser
Can trapped investors hope for a rebound in Beam Therapeutics Inc.July 2025 Chart Watch & Verified Momentum Watchlists - Newser
Understanding Beam Therapeutics Inc.’s price movementWeekly Earnings Recap & Accurate Intraday Trading Signals - Newser
Evaluating Beam Therapeutics Inc. with trendline analysisJuly 2025 Retail & AI Based Buy/Sell Signal Reports - Newser
Beam Therapeutics shares fall 3.73% intraday after presenting at Citi's Biopharma Back. - AInvest
Russell Investments Group Ltd. Lowers Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Will Beam Therapeutics Inc. rebound enough to break even2025 Top Decliners & Consistent Return Investment Signals - Newser
Analyzing Beam Therapeutics Inc. with multi timeframe charts2025 Price Momentum & Risk Controlled Stock Alerts - Newser
Combining price and volume data for Beam Therapeutics Inc.Market Performance Recap & Reliable Breakout Forecasts - Newser
Sentiment analysis tools applied to Beam Therapeutics Inc.Weekly Gains Summary & Verified Entry Point Signals - Newser
Beam Therapeutics’ Strategic Position in Base Editing and Pipeline Progress - AInvest
Chart based analysis of Beam Therapeutics Inc. trendsMarket Trend Review & Safe Capital Preservation Plans - Newser
Beam Therapeutics’ Unexpected Surge: Analyzing the Latest Performance - StocksToTrade
US Stocks Recap: Will Beam Therapeutics Inc. benefit from AI trendsMarket Trend Summary & Reliable Breakout Forecasts - خودرو بانک
Beam Therapeutics’ Stock Soars as Cathie Wood’s ARK Buys Shares - timothysykes.com
Beam Therapeutics Surges 13% on Intraday Rally – What’s Fueling the Momentum? - AInvest
Is this a good reentry point in Beam Therapeutics IncTrade Risk Report & AI Based Buy and Sell Signals - Newser
Applying Elliott Wave Theory to Beam Therapeutics Inc.July 2025 Earnings & Trade Opportunity Analysis Reports - Newser
Intraday pattern recognizer results for Beam Therapeutics IncJuly 2025 Setups & AI Forecast Swing Trade Picks - Newser
Can trapped investors hope for a rebound in Beam Therapeutics IncWeekly Loss Report & Free Growth Oriented Trading Recommendations - Newser
Intraday pattern recognizer results for Beam Therapeutics Inc.2025 Retail Activity & Free Real-Time Market Sentiment Alerts - Newser
Is Beam Therapeutics Inc. forming a reversal patternJuly 2025 Pullbacks & AI Forecasted Entry and Exit Points - Newser
Market reaction to Beam Therapeutics Inc.’s recent news2025 Buyback Activity & Reliable Momentum Entry Alerts - Newser
Beam Therapeutics Inc. stock outlook for YEARInsider Buying & High Conviction Investment Ideas - Newser
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.33%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):